TY  - JOUR
T1  - CArdiovascular risk assessment in the development of new drugs for obesity
AU  - Hiatt WR, Goldfine AB, Kaul S
Y1  - 2012/09/19
N1  - 10.1001/jama.2012.9931
JO  - JAMA
SP  - 1099
EP  - 1100
VL  - 308
IS  - 11
N2  - 
The US Food and Drug Administration (FDA), Center for Drug Evaluation and Research, convened a meeting of the Division of Metabolism and Endocrinology Products on March 28-29, 2012, to consider cardiovascular safety requirements for approval of new drugs to treat obesity. The broader context at that time involved 4 recent individual drug product reviews, resulting in no new antiobesity drugs approved and 1 drug (sibutramine) withdrawn from the market.1 For pharmacologic weight loss to be more than cosmetic, it is essential to demonstrate measurable health benefits. Because obesity is associated with excess cardiovascular risk and weight loss treatments could potentially mitigate that risk, it is important to assess the effect of these drugs on cardiovascular morbidity and mortality.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2012.9931
UR  - http://dx.doi.org/10.1001/jama.2012.9931
ER  -